GAITHERSBURG, Md., Feb. 9 /PRNewswire-FirstCall/ -- Iomai Corporation today announced that Stanley C. Erck, the company’s president and chief executive officer, will speak at the 9th Annual BIO CEO & Investor Conference on Tuesday, February 13 at 9:45 a.m. Eastern Time. In addition, Mr. Erck will take part in a panel discussion, “The Pandemic Panic,” taking place Monday, February 12 at 9:30 a.m.
In his presentation, Erck will give an overview of the $128 million government contract for the study of a dose-sparing patch for use with a pandemic influenza vaccine, awarded to Iomai last month, as well as details on the company’s three clinical patch-based vaccine programs.
The conference is being held at the Waldorf-Astoria Hotel in New York.
Iomai last month announced that it would receive a contract from the Department of Health and Human Services (DHHS) to fund the company’s development of a dose-sparing patch for use with a pandemic influenza vaccine. If the product is developed through licensure, the total cost reimbursed by DHHS, plus the fixed fee, is estimated to be $128 million.
To access the live audio webcast or the subsequent archived recording, log on to the Investor Relations section on the Overview page of the Iomai website at www.iomai.com. Please connect to Iomai’s website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.
ABOUT IOMAI CORPORATION
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers’ diarrhea. For more information on Iomai, please visit www.iomai.com.
Iomai Corporation
CONTACT: Russell P. Wilson, Senior Vice President, Chief Financial Officerand General Counsel, Iomai Corporation, +1-301-556-4478, orinvestors@iomai.com; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626, or breid@weisscommpartners.com, for Iomai Corporation
Web site: http://www.iomai.com/
